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In this issue of Cell Stem Cell, the seminal work of Ginestier et al. (2007) elegantly demonstrates that
aldehyde dehydrogenase 1 (ALDH1) facilitates the identification and isolation of normal and malig-
nant human mammary stem cells in vitro, in vivo, and in situ in fixed tissues.Challenging the classical dogma of
the stochastic model of breast cancer
requires thinking outside the box. As
breast cancer treatment failures con-
tinue, it has become necessary to pro-
pose alternative paradigms in oncol-
ogy and therapeutic strategies based
on mammary cell biology to improve
clinical outcomes and patient survival.
In this issue ofCell StemCell, Ginestier
et al. (2007) brilliantly rise to this chal-
lenge and lend support to the cancer
stem cell hypothesis via their elegant
strategy and seminal results that
demonstrate that the first isoform of
aldehyde dehydrogenase (ALDH1) is
a marker of normal and malignant
human mammary stem cells and a pre-
dictor of poor clinical outcome.
In contrast to the stochastic model,
where every cancer cell has the poten-
tial to give rise to a new tumor, the can-
cer stem cell model suggests that only
a few cells have the intrinsic capacity
to generate new tumors (Balicki et al.,
2007). Unlike their murine counter-
parts, studies of human mammary
stem and progenitor cells have been
limited by the challenges associated
with the identification of human mam-
mary stem cell markers across histo-
logical subtypes in suitable in vivo xen-
otransplantation assays. Our growing
understanding of the importance of
the stem cell niche underscores the
complexity of xenotransplantation,
where the humanization of mouse tis-
sues is used to support the growth of
human cells.To overcome the challenge pre-
sented by the limited availability of
stem cell markers, fluorescent dyes
have been utilized to identify and iso-
late ‘‘side populations’’ using flow cy-
tometry (Hadnagy et al., 2006). These
studies are based on the capacity of
stem cell populations to efficiently
efflux dyes such as Hoechst 33342.
However, the toxicity associated with
the Hoechst 33342 dye has precluded
its use for the selection of cell popula-Cell Stem Cell 1,tions for functional stem cell assays
in vivo (Balicki and Beaulieu, 2007).
Due to the growing need for new
markers to identify and isolate stem
cells, assays based on ALDH activity
have been proposed as a promising
alternative. ALDH is a family of cyto-
solic isoenzymes responsible for oxi-
dizing intracellular aldehydes, leading
to the oxidation of retinol to retinoic
acid in early stem cell differentiation.
ALDH1 is the predominant ALDHFigure 1. The ALDEFLUOR Assay
The ALDEFLUOR assay is illustrated in (A) ALDH-negative cells and (B) ALDH-positive cells. In the
presence of dimethylsulfoxide (DMSO) and acid, BAAA-DA Bodipy-aminoacetaldehyde diethyl
acetal (BAAA-DA) is converted to the ALDH substrate Bodipy-aminoacetaldehyde (BAAA), which
diffuses freely across the plasma membrane of intact viable cells. Intracellular ALDH converts
BAAA into the fluorescent product BAA (BODIPY-aminoacetate). In the presence of ALDH, cellular
fluorescence can be detected with the green fluorescence channel of a standard flow cytometer
and compared with treatment using the ALDH inhibitor diethylamino-benzaldehyde (DEAB) as
a negative control (https://www.stemcell.com).November 2007 ª2007 Elsevier Inc. 485
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and Breast Carcinomas
Cancer stem cells (CSCs) are tumor-initiating cells that may arise from the dysregulation of normal
stem cells (NSCs) or mutated progenitor cells. Stem cells self-renew and differentiate. NSCs may
divide asymmetrically to produce an NSC and a differentiated cell. In contrast, cancer stem cells
(CSCs) may divide symmetrically, giving rise to two CSCs and resulting in clonal expansion. CSCs
may also give rise to aberrantly differentiated cells. ALDH1 is a marker of stem/progenitor cells of
the normal human breast and breast carcinomas, and high ALDH1 levels may identify the tumor-
igenic cell fraction of breast carcinomas. Modified with permission. Copyright (ª2007). From
‘‘Breast Cancer Stem Cells and Their Niche: Lethal Seeds in Lethal Soil,’’ by D. Balicki, B. Leyland-
Jones, and M.S. Wicha/In Pharmacogenetics of Breast Cancer: Towards the Individualization of
Therapy, B. Leyland-Jones ed. Reproduced by permission of Informa Healthcare USA Inc., a divi-
sion of Informa plc (Balicki et al., 2007).isoform in mammals that regulates
the conversion of retinaldehydes to
retinoic acids (Chute et al., 2006). In-
creased ALDH activity has been de-
scribed in human hematopoietic cells
(Hess et al., 2004) and also in cancers
of multiple tissues, including the pan-
creas (Jelski et al., 2007) and the lung
(Minegishi et al., 2007).
In this issue, Ginestier et al. (2007)
masterfully overcome the toxicity as-
sociated with the Hoechst 33342 dye
by using the ALDEFLUOR assay,
optimized to detect ALDH1 activ-
ity (https://www.stemcell.com). The
ALDEFLUOR assay detects intracellu-
lar ALDH expression in viable cells by486 Cell Stem Cell 1, November 2007 ª2using the green fluorescence channel
of a standard flow cytometer (Figure 1).
Because ALDEFLUOR-positive cells
are viable and selectable by using flow
cytometric cell sorting based on their
fluorescence, they are readily available
for stem cell studies both in vitro and
in vivo. In addition, the ALDEFLUOR
assay detects ALDH activity rather
than cell surface phenotype. Thus, it
overcomes the necessity to identify
specific cell surface markers that dis-
criminate stem and progenitor cells
from their differentiated progeny, the
expression of which may also be
dynamic and influenced by the local
microenvironment. Given that cancer007 Elsevier Inc.cells result from the accumulation of
mutations in their normal counterparts,
and mutations in progenitor cells may
lead to the emergence of stem cell
properties in these more differentiated
cells, it is conceivable that a functional
marker may be common to normal and
cancerous stem and progenitor cells
(Figure 2).
Although limited growth was ob-
served when 50,000 ALDEFLUOR-
negative cells were injected, using
purified populations of as few as 500
ALDEFLUOR-positive cells isolated
from the same tumors, Ginestier et al.
(2007) successfully formed tumors
within as few as 40 days in a NOD/
scid xenotransplant model. In addi-
tion, successive transplantation of
a population that recapitulated the
phenotypic heterogeneity of the initial
tumor, including a similar ratio of
ALDEFLUOR-positive and -negative
cells, resulted in serial passaging of
the original tumor. This result is partic-
ularly exciting given that the popula-
tion was isolated based on a single
parameter, in contrast to the minimum
of 10 markers used previously to
select CD44+/CD24/lin tumor-initi-
ating cells (Al-Hajj et al., 2003). The
ALDEFLUOR-positive population over-
laps only in part with the previously
described CD44+/CD24/lin pheno-
type (Al-Hajj et al., 2003). Combining
these cell surface and ALDEFLUOR
activity-based isolation schemes
yields an enriched population of highly
tumorigenic cells, generating tumors
from as few as 20 cells. This spectac-
ular result represents at least a 5-fold
improvement over the minimum of
100 CD44+/CD24/low/lin human
cells previously shown to form xeno-
graft tumors in mice (Al-Hajj et al.,
2003). ALDH plays a critical role in
human hematopoietic stem cell (HSC)
differentiation, and its inhibition is
sufficient to induce the amplification
of human HSCs (Chute et al., 2006).
Ginestier et al. confirmed the capacity
of ALDEFLUOR-positive cells to differ-
entiate, which, when taken together
with their self-renewal capacity as
demonstrated in serial passage, con-
firm that ALDH activity is a promising
stem cell marker candidate, as its
activity is associated with the self-re-
newal and differentiation properties
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ALDH1 immunostaining of patient
samples revealed that ALDH1 expres-
sion correlates with a poor clinical
outcome in both an American and
a French data set of breast carcino-
mas. Results from my own laboratory
independently confirm this correlation
by ALDH1 immunostaining of fixed
human breast cancer samples (Balicki
et al., 2007). Thus, ALDH1 assays are
readily available and can be added to
the currently available panel of diag-
nostic markers used to improve the
accuracy of clinical outcome predic-
tions and the choice of appropriate
therapy.
In conclusion, ALDH1 is a pivotal
tool for isolation of populations en-
riched in tumor-initiating function,
lending support to stem cell hypothe-
sis and the model that normal and can-
cer stem and progenitor cells share
conserved cellular activities. Its com-
bination with the selection of the
CD44+/CD24/lin phenotype sets a
milestone, as it yields the most highly
tumorigenic human cell population
isolated thus far and concomitantly
overcomes many of the barriers asso-
ciated with xenotransplantation. Fu-
ture advancements in human mam-
mary stem cell biology may arise
from studies that utilize murine models
that exhibit greater immunodeficiency
than NOD/scid mice, such as NOD/scid IL2Rgammanull mice, which have
very limited natural killer (NK) cell
activity (http://jaxmice.jax.org/strain/
005557.html). Xenotransplantation
studies may be refined even further,
as an improved understanding of the
nature and respective quantities of
the components of the stem cell niche
is developed to help optimize tumor
cell growth. For example, a recent
study suggests that mesenchymal
stem cells within tumor stroma promote
breast cancer metastases (Karnoub
et al., 2007). Thus, ALDH1 activity fa-
cilitates the identification and isolation
of lethal cancer seeds in lethal soil,
thereby fuelling our quest to prevent
the longevity of cancer stem cells
within their niche from interfering with
our own. It also sets a solid foundation
for future studies in animal models that
hold great promise for the develop-
ment of novel breast cancer preven-
tion and therapeutic strategies using
state-of-the-art individualized treat-
ments for breast cancer patients.
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